Shanghai Tissue bank Biotechnology Co., Ltd. was incorporated in August 2013 and completed the construction of a 200m2 in vitro diagnostic reagent production workshop in 2014.
Relying on the well-established molecular detection and medical diagnostic platform of Besenberg, genetic immunity is the focus of product research and development. Established an industrial pathway for clinical research and clinical application to product landing.Among them, hematopoietic stem cell transplantation was established to establish a pre-operative diagnosis, donor-growth matching and prognosis evaluation of patients with prognosis, and gained market recognition. A number of services have entered the final sprint of the product landing, in which the nucleic acid extraction kit has obtained the medical device registration certificate, the HLA typing kit (SBT method) has completed the clinical trial, and a number of other preoperative diagnostic reagents and prognostic evaluation reagents have also been activated. Conversion from service to product.With the deepening of the field of genetics and immunity in the field of tumors, there are also a series of fist products in the field of tumor immunity and neuroimmunity, and then the masters of Beacon Biotechnology will actively promote the products in the fields of tumor immunity and neuroimmunity.